Downloaded from heart.bmj.com on October 6, 2014 - Published by group.bmj.com
Editorial
Ivabradine and atrial fibrillation: what should we tell our patients? Martin R Cowie Ivabradine selectively blocks the If channel by binding to a site in the channel pore, reducing the f-current and thereby reducing the slope of the slow diastolic depolarisation phase of the action potential in the sinoatrial node cells, increasing the time required to reach the voltage threshold for action potential initiation. This slows the spontaneous firing of the sinoatrial node cells and, therefore, the heart rate (HR). The drug is licensed for the treatment of angina and of systolic heart failure in sinus rhythm. At therapeutic doses the drug does not act on other cardiac ion currents and there appears to be no direct effects on myocardial contractility or relaxation, cardiac output, coronary haemodynamics, blood pressure or peripheral resistance in humans. The molecular subunits of the If channel are the hyperpolarisation-activated cyclic-nucleotide gated (HCN) channels. Polymorphism in these proteins may explain some of the variation in resting HR in human populations. Several genetic alterations of the HCN4 channel gene have been reported to be associated with asymptomatic sinus bradycardia, sinus arrhythmia and atrial fibrillation (AF). There is some evidence of more widespread If channel expression in disease states, and in other species, including in pulmonary vein myocytes in the rabbit.1 Ruairidh and colleagues2 raise the possibility that ivabradine may affect the electrical properties of pulmonary venous myocardium, increasing the risk of AF. They have conducted a meta-analysis of randomised trials with this drug, and report a 15% increase in the relative risk of AF. They postulate that there may be individual variation in susceptibility to this side effect, related to polymorphisms in HCN4 or other HR regulating genes.
WHAT IS THE EVIDENCE THAT IVABRADINE INCREASES THE RISK OF AF? The summary of product characteristics in the European Union (EU) recommends ‘to regularly clinically monitor ivabradine treated patients for the occurrence of AF Correspondence to Professor Martin R Cowie, Imperial College London, London, UK; [email protected]
(sustained or paroxysmal), which should also include ECG monitoring if clinically indicated (eg, in case of exacerbated angina, palpitations, irregular pulse). The risk of developing AF may be higher in patients with chronic heart failure treated with ivabradine. AF has been more common in patients using concomitantly amiodarone or potent class I antiarrhythmics.’ So the risk is obviously recognised. AF is listed as a ‘very rare’ adverse reaction (
Editorial
Ivabradine and atrial fibrillation: what should we tell our patients? Martin R Cowie Ivabradine selectively blocks the If channel by binding to a site in the channel pore, reducing the f-current and thereby reducing the slope of the slow diastolic depolarisation phase of the action potential in the sinoatrial node cells, increasing the time required to reach the voltage threshold for action potential initiation. This slows the spontaneous firing of the sinoatrial node cells and, therefore, the heart rate (HR). The drug is licensed for the treatment of angina and of systolic heart failure in sinus rhythm. At therapeutic doses the drug does not act on other cardiac ion currents and there appears to be no direct effects on myocardial contractility or relaxation, cardiac output, coronary haemodynamics, blood pressure or peripheral resistance in humans. The molecular subunits of the If channel are the hyperpolarisation-activated cyclic-nucleotide gated (HCN) channels. Polymorphism in these proteins may explain some of the variation in resting HR in human populations. Several genetic alterations of the HCN4 channel gene have been reported to be associated with asymptomatic sinus bradycardia, sinus arrhythmia and atrial fibrillation (AF). There is some evidence of more widespread If channel expression in disease states, and in other species, including in pulmonary vein myocytes in the rabbit.1 Ruairidh and colleagues2 raise the possibility that ivabradine may affect the electrical properties of pulmonary venous myocardium, increasing the risk of AF. They have conducted a meta-analysis of randomised trials with this drug, and report a 15% increase in the relative risk of AF. They postulate that there may be individual variation in susceptibility to this side effect, related to polymorphisms in HCN4 or other HR regulating genes.
WHAT IS THE EVIDENCE THAT IVABRADINE INCREASES THE RISK OF AF? The summary of product characteristics in the European Union (EU) recommends ‘to regularly clinically monitor ivabradine treated patients for the occurrence of AF Correspondence to Professor Martin R Cowie, Imperial College London, London, UK; [email protected]
(sustained or paroxysmal), which should also include ECG monitoring if clinically indicated (eg, in case of exacerbated angina, palpitations, irregular pulse). The risk of developing AF may be higher in patients with chronic heart failure treated with ivabradine. AF has been more common in patients using concomitantly amiodarone or potent class I antiarrhythmics.’ So the risk is obviously recognised. AF is listed as a ‘very rare’ adverse reaction (
